Previous 10 | Next 10 |
- The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90% - Results pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening - The company will host a webcast and conference call to discuss th...
Innovation drives progress, and in the healthcare sector, that often means saving lives by finding new ways to diagnose or treat potentially deadly illnesses. Those companies at the forefront of innovation can help improve the lives of thousands of people while providing outsized returns to inves...
Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, ann...
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers, co-occurring mutations and molecular response to therapy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new dat...
Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...
Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...
Guardant Health, Inc. (GH) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell ...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Guardant Health, Inc. 2022 Q3 - Results - Earnings Call Presentation
Guardant Health press release ( NASDAQ: GH ): Q3 Non-GAAP EPS of -$1.18 misses by $0.10 . Revenue of $117.4M (+23.9% Y/Y) misses by $0.5M . Adjusted EBITDA loss was $112.8M for the third quarter of 2022, as compared to a $65.2M loss for the corresponding prior ...
Q3 clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...